Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.

Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.

Brivanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) tyrosine kinases, which are both involved in mechanisms of liver fibrosis. We hypothesized that inhibition of VEGFR and FGFR by brivanib would inhibit liver fibrosis....

Full description

Bibliographic Details
Main Authors: Ikuo Nakamura, Kais Zakharia, Bubu A Banini, Dalia S Mikhail, Tae Hyo Kim, Ju Dong Yang, Catherine D Moser, Hassan M Shaleh, Sarah R Thornburgh, Ian Walters, Lewis R Roberts
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3977817?pdf=render

Internet

http://europepmc.org/articles/PMC3977817?pdf=render

Similar Items